Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

  • Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammation
  • Novel bispecific design shows promising potential manufacturability and stability to support high dosing concentration and subcutaneous administration
  • Regulatory filing to support Phase 1 studies expected in 2H-2026

VANCOUVER, British Columbia, May 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of new preclinical data for ZW1528, a novel IL-4Rα x IL-33 bispecific molecule designed to address respiratory inflammation, at the American Thoracic Society (ATS) International Conference being held May 18-21, 2025 in San Francisco, CA.

“Our expansion into autoimmune and inflammatory diseases represents a carefully considered R&D strategy to leverage our expertise in multispecific antibodies to deliver meaningful impact for patients with difficult-to-treat respiratory disorders,” said Paul Moore, Ph.D., Chief Scientific Officer of Zymeworks. “The preclinical data presented at ATS demonstrate that ZW1528 binds with high affinity to both IL-4Rα and IL-33, driving potent blockade of two distinct signaling axes implicated in inflammatory disease, including chronic obstructive pulmonary disease (COPD). With its unique dual mechanism of action, ZW1528, which was created using our proprietary AzymetricÔ technology, may translate to better control of COPD in a broader patient population compared to existing therapies.”

Key findings for ZW1528 include:

  • High-affinity binding to both IL-33 and IL-4Rα and effective blockade of IL-4, IL-13, and IL-33 signaling at levels comparable to clinical benchmark monoclonal antibody controls.
  • Suppression of both Type 2 and non-Type 2 responses in primary human immune cells of COPD patients in vitro.
  • Efficacy in vivo in acute and chronic murine models of lung inflammation driven by house dust mites.
  • Extended pharmacokinetics in rodent and non-human primate models, with incorporation of Fc extending half-life optimization.
  • Biophysical stability at high concentration (150 mg/mL), supporting potential for subcutaneous administration.

Poster Presentation Details:

Title: ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Abstract Number: 2982
Session Category: B33 – WHEEZING THROUGH THE MECHANISMS: UNPACKING ASTHMA’S SECRETS
Session Title: Thematic Poster Session
Poster Board: P1567
Date and Time: May 19, 2025 at 11:30 am – 1:15 pm Pacific Time

Beyond ZW1528, Zymeworks is also developing ZW1572, a bispecific inhibitor of IL-4Rα and IL-31 for atopic dermatitis, as part of its growing IL-4Rα program portfolio. The Company continues to advance additional product candidates in multiple formats across selected therapeutic indications in AIID and hematological cancers, with further Investigational New Drug and equivalent non-U.S. application submissions planned for 2028 and beyond.

Additional information can be found on the ATS website, and a copy of the poster is available on the Publications page of Zymeworks’ website.

About ZW1528

ZW1528 is a novel IL-4R⍺ x IL-33 bispecific molecule designed to address respiratory inflammation such as mixed-type chronic obstructive pulmonary disease (COPD) by inhibiting multiple pathways. By blocking three cytokines (IL-4, IL-13 and IL-33) in a single biologic, ZW1528 offers a unique approach to inhibit clinically validated pathways. The bispecific antibody is designed to provide complete, prolonged IL-4R⍺ blockade with simultaneous blockade of IL-33. Based on non-clinical in vitro studies, the bispecific can independently suppress IL-13, IL-4, and IL-33 driven cell signaling equivalent to that achieved with anti-IL-4R⍺ monoclonal antibody (mAb) or anti-IL-33 clinical benchmarks mAbs. Furthermore, in preclinical studies, ZW1528-mediated blockade of cytokine-driven activation of human epithelial cells was superior to that achieved with mAbs targeting either IL-4R⍺ or IL-33, indicating potential benefits of dual blockade. Additionally, preclinical studies with human peripheral blood mononuclear cells demonstrate ZW1528 provides blockade of IL-33 mediated effects beyond that achievable with an anti-IL33 benchmark mAb. With native Immunoglobulin G-like geometry, ZW1528 demonstrates the potential for high manufacturability and incorporates half-life extending Fc modifications.

About Zymeworks Inc.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned for mid-2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ preclinical data presentations and key findings; the timing and status of ongoing and future studies and the release of data; the potential therapeutic effects of and commercial potential of Zymeworks’ product candidates; Zymeworks’ preclinical pipeline; anticipated IND submissions and the timing thereof; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “anticipate”, “potential”, “will”, “on track”, “continues”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty and new policies implemented under the current administration, including executive orders, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; clinical trials and any future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com


Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference


THỦ THUẬT HAY

Mua laptop Alien hay build PC để dựng video + After Effect?

Qua tìm hiểu thì cũng ngắm được vài em Alien trong tầm chi trả, nhưng cũng có vài anh em chia sẻ là nên dựng PC ở nhà.

Hướng dẫn cách thu nhỏ giao diện của Task Manager

Task Manager là một tính năng quan trọng cho người dùng Windows. Với công cụ này, người dùng có thể làm được nhiều công việc khác nhau như kiểm tra các ứng dụng, quá trình (process) và dịch vụ (service) hiện đang chạy

EaseUS Partition Master: Thay đổi kích cỡ hoặc di chuyển phân vùng ổ cứng

EaseUS Partition Master giúp thay đổi kích cỡ / di chuyển phân vùng ổ cứng để tận dụng không gian đĩa đặc biệt là mở rộng hệ thống ổ đĩa (ổ đĩa C) để giải quyết vấn đề dung lượng lưu trữ ổ cứng thấp

Đây là cách ẩn ứng dụng ở màn hình chính iPhone trên iOS 15 bạn nên lưu ngay

Người dùng iPhone trước đây chắc hẳn sẽ có những ứng dụng riêng tư nhưng không thể ẩn chúng đi ở ngoài màn hình chính, nhưng với iOS 15, bạn đã có thể ẩn đi một hoặc nhiều ứng dụng một cách dễ dàng.

Hướng dẫn xem trực tiếp bóng đá Sea Games 29 qua mạng

SEA Games 29 đã chính thức khởi tranh lúc 15h00 chiều ngày 14/8, toàn bộ các trận đấu sẽ tường thuật trực tiếp trên kênh VTV6 và VTV6 HD.

ĐÁNH GIÁ NHANH

Energizer UE20100CQ pin dự phòng không thể thiếu cho những chuyến du lịch

Với những chuyến đi xa hoặc những ai có nhu cầu trang bị theo mình một pin dự phòng “trâu bò” nhưng phải bảo đảm chất lượng thì Energizer UE20100CQ chắc chắn là sự lựa chọn hoàn hảo. Energizer là thương hiệu đến từ Mỹ,

Đánh giá nhanh Vivo Y71: Lựa chọn phù hợp cho người dùng có ít kinh phí

Nhìn vào mặt trước, Vivo Y71 trông không hề khác biệt so với những thiết bị đắt tiền hơn. Nó có viền 2 bên rất mỏng, gần như không tồn tại, trong khi viền ở cạnh trên và dưới cũng được thu hẹp đáng kể, tạo nên vẻ đẹp

Trên tay Jabra 710 - loa chuyên dùng cho thoại hội nghị

Nếu bạn thường xuyên phải họp hội nghị qua điện thoại, hoặc thường xuyên nghe điện thoại bằng loa ngoài (speaker phone) thì loa Jabra 710 này có khả năng đáp ứng được nhu cầu của bạn.